(Q47921377)

English

Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.

scientific article published on 19 January 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28404157

Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. (English)

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28404157

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

Kazuhiro Yoshida

12

object named as

Kazuhiro Yoshida

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28404157

author name string

Kohei Shitara

1

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28404157

Atsuo Takashima

2

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28404157

Kazumasa Fujitani

3

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28404157

Keisuke Koeda

4

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28404157

Hiroki Hara

5

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28404157

Norisuke Nakayama

6

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28404157

Shuichi Hironaka

7

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28404157

Kazuhiro Nishikawa

8

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28404157

Yoichi Makari

9

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28404157

Kenji Amagai

10

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28404157

Shinya Ueda

11

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28404157

Hideki Shimodaira

13

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28404157

Tomohiro Nishina

14

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28404157

Masahiro Tsuda

15

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28404157

Yukinori Kurokawa

16

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28404157

Takao Tamura

17

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28404157

Yasutsuna Sasaki

18

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28404157

Satoshi Morita

19

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28404157

Wasaburo Koizumi

20

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28404157

publication date

19 January 2017

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28404157

The lancet. Gastroenterology & hepatology

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28404157

2

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28404157

4

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28404157

277-287

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28404157

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930219-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930219-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930219-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930219-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 400

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930219-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930219-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930219-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacology and toxicology of Cremophor EL diluent

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930219-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930219-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930219-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930219-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930219-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930219-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930219-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930219-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized Phase III trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE Trial).

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930219-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930219-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930219-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930219-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930219-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2468-1253(16)30219-9

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28404157

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28404157

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47921377&oldid=1746373137"